《新股消息》內地醫療AI龍頭訊飛醫療科技向港交所申請IPO 服務逾5萬家基層醫療機構
科大訊飛(002230.SZ)旗下訊飛醫療科技正式向港交所(00388.HK)提交上市申請書。分拆上市完成後,科大訊飛仍將維持對訊飛醫療的控制權,訊飛醫療仍為公司合併報表範圍內的控股子公司。
科大訊飛表示,分拆上市後,訊飛醫療將擁有獨立融資平台並借此深耕主營業務,有利於增強訊飛醫療在醫療行業進行技術儲備及市場開拓的能力,通過提升市場綜合競爭力而提升公司未來整體盈利水平。
據上市申請書顯示,訊飛醫療致力於打造每個醫生的AI診療助理、每個居民的AI健康助手。截至最後實際可行日期,訊飛醫療向約52,000家基層醫療機構提供產品及服務,涵蓋逾30個省份、400個區縣,以及逾400家醫院,包括內地首七家大型醫院。
業績方面,訊飛醫療的收入由2021年的3.73億元人民幣(下同)增26.7%至2022年的4.72億元,其由截至2022年9月30日止九個月的2.51億元增29%至截至2023年9月30日止九個月的3.24億元。毛利亦由2021年的1.88億元增22.9%至2022年的2.31億元,並由截至2022年9月30日止九個月的1.3億元增38.1%至截至2023年9月30日止九個月的1.79億元。
不過,由於投入大量資源在研發方面,於2021年、2022年、截至2022年及2023年9月30日止九個月,訊飛醫療分別錄得虧損淨額8,940萬元、2.09億元、1.63億元和1.7億元。雖然營業收入大幅增長,但虧損並未見有收窄跡象。(ta/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.